<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25996152</article-id><article-id pub-id-type="pmc">4440619</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0127564</article-id><article-id pub-id-type="publisher-id">PONE-D-15-07522</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Online Training on Skin Cancer Diagnosis in Rheumatologists: Results from a Nationwide Randomized Web-Based Survey</article-title><alt-title alt-title-type="running-head">Online Training on Skin Cancer Diagnosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Viguier</surname><given-names>Manuelle</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Rist</surname><given-names>St&#x000e9;phanie</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aubin</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leccia</surname><given-names>Marie-Th&#x000e9;r&#x000e8;se</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Richard</surname><given-names>Marie-Aleth</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Esposito-Far&#x000e8;se</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gaudin</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Thao</given-names></name><xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Richette</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wendling</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff010">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sibilia</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="aff011">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tubach</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><collab>Club Rhumatismes et Inflammation</collab><xref ref-type="author-notes" rid="fn001">
<sup>&#x000b6;</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Universit&#x000e9; Paris Diderot, Sorbonne Paris Cit&#x000e9;, Paris, France; Assistance-Publique H&#x000f4;pitaux de Paris (APHP), H&#x000f4;pital Saint-Louis, Service de Dermatologie, Paris, France</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Service de Rhumatologie, Centre Hospitalier R&#x000e9;gional (CHR), Orl&#x000e9;ans, France</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Universit&#x000e9; de Franche Comt&#x000e9;, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besan&#x000e7;on, France</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Clinique de Dermatologie, Allergologie et Photobiologie, CHU, Grenoble, France</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Service de Dermatologie, Universit&#x000e9; Aix-Marseille, Centre de recherche en oncologie biologique et oncopharmacologie, H&#x000f4;pital de la Timone, Assistance Publique H&#x000f4;pitaux de Marseille, Marseille, France</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>Universit&#x000e9; Paris Diderot, Sorbonne Paris Cit&#x000e9;, UMR 1123, Paris, France; APHP, H&#x000f4;pital Bichat, D&#x000e9;partement d&#x02019;Epid&#x000e9;miologie et Recherche Clinique, Centre de Pharmaco-&#x000e9;pid&#x000e9;miologie (C&#x000e9;ph&#x000e9;pi), Paris, France; INSERM, CIC-EC 1425, UMR 1123, Paris, France</addr-line>
</aff><aff id="aff007">
<label>7</label>
<addr-line>Clinique Universitaire de Rhumatologie, CHU H&#x000f4;pital Sud, Grenoble, France</addr-line>
</aff><aff id="aff008">
<label>8</label>
<addr-line>Service de Rhumatologie, CHU, APHM, Marseille, France</addr-line>
</aff><aff id="aff009">
<label>9</label>
<addr-line>Universit&#x000e9; Paris Diderot, APHP, H&#x000f4;pital Lariboisi&#x000e8;re, Service de Rhumatologie, Paris, France</addr-line>
</aff><aff id="aff010">
<label>10</label>
<addr-line>Universit&#x000e9; de Franche Comt&#x000e9;, Service de Rhumatologie, CHU, Besan&#x000e7;on, France</addr-line>
</aff><aff id="aff011">
<label>11</label>
<addr-line>INSERM UMR_S1109, Centre de Recherche d&#x02019;Immunologie et d&#x02019;H&#x000e9;matologie, F&#x000e9;d&#x000e9;ration de m&#x000e9;decine translationelle, Universit&#x000e9; de Strasbourg, Strasbourg, France</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Lo</surname><given-names>Anthony W.I.</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Queen Mary Hospital, HONG KONG</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors received funding from a commercial source, Abbvie Ltd. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: MV SR FA MTL MAR PG TP PR DW JS FT. Performed the experiments: MV SR FA MTL MAR PG TP PR DW. Analyzed the data: MV SR FA MTL MAR PG TP PR DW MEF FT. Contributed reagents/materials/analysis tools: MV SR FA MTL MAR PG TP PR DW JS FT. Wrote the paper: MV SR FA MTL MAR PG TP PR DW MEF FT. Statistical analysis: MEF FT.</p></fn><fn fn-type="other" id="fn001"><p>&#x000b6; The complete membership of the author group can be found in the Acknowledgments.</p></fn><corresp id="cor001">* E-mail: <email>manuelle.viguier@sls.aphp.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>5</issue><elocation-id>e0127564</elocation-id><history><date date-type="received"><day>26</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Viguier et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Viguier et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0127564.pdf"/><abstract><p>Patients with inflammatory rheumatisms, such as rheumatoid arthritis, are more prone to develop skin cancers than the general population, with an additional increased incidence when receiving TNF blockers. There is therefore a need that physicians treating patients affected with inflammatory rheumatisms with TNF blockers recognize malignant skin lesions, requiring an urgent referral to the dermatologist and a potential withdrawal or modification of the immunomodulatory treatment. We aimed to demonstrate that an online training dedicated to skin tumors increase the abilities of rheumatologists to discriminate skin cancers from benign skin tumors. A nationwide randomized web-based survey involving 141 French rheumatologists was conducted. The baseline evaluation included short cases with skin lesion pictures and multiple choice questions assessing basic knowledge on skin cancers. For each case, rheumatologists had to indicate the nature of skin lesion (benign; premalignant/malignant), their level of confidence in this diagnosis (10-points Likert scale), and the precise dermatological diagnosis among 5 propositions. Different scores were established. After randomization, only one group had access to the online formation consisting in 4 e-learning modules on skin tumors, of 15 minutes each (online training group). After reevaluation, the trained and the non-trained group (control group) were compared. The primary end-point was the number of adequate diagnoses of the nature of the skin lesions. The mean number of adequate diagnosis for the benign versus premalignant/malignant nature of the lesions was higher in the online training group (13.4 vs. 11.2 points; <italic>p</italic> value &#x0003c;0.0001). While the other knowledge scores were also significantly higher, no statistical difference was observed on the level of self-confidence between the 2 groups. In conclusion, the online formation was effective to improve the rheumatologists&#x02019; ability to diagnose skin cancer.</p></abstract><funding-group><funding-statement>The study was supported by an unrestricted grant from Abbvie Ltd. The funder had no role in study design, analysis, decision to publish or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="9"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>A baseline increased risk of skin cancers in Rheumatoid arthritis (RA) patients compared to the general population has been reported, with a 40% increase risk of squamous cell carcinoma (SCC) and a 30% relative increase in basal cell carcinoma (BCC), and a further increase in patients receiving TNF inhibitors [<xref rid="pone.0127564.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0127564.ref008" ref-type="bibr">8</xref>]. Meta-analysis from 4 prospective observational studies in RA patients showed a pooled risk estimate for non-melanoma skin cancers in patients receiving TNF blockers of 1.33 (95%CI 1.06 to 1.60), with similar results observed in a meta-analysis of randomized controlled trials (RR 2.02, 95%CI 1.11 to 3.95) [<xref rid="pone.0127564.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0127564.ref007" ref-type="bibr">7</xref>]. Two registries showed about a 2-fold increased risk of developing melanoma when receiving TNF inhibitor [<xref rid="pone.0127564.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0127564.ref008" ref-type="bibr">8</xref>].</p><p>Accordingly, several national and international recommendations regarding skin cancers have been established for patients affected with inflammatory rheumatism [<xref rid="pone.0127564.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0127564.ref010" ref-type="bibr">10</xref>].</p><p>Because of a limited access to a dermatologist in several countries [<xref rid="pone.0127564.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0127564.ref012" ref-type="bibr">12</xref>], there is therefore a need that physicians treating patients affected with inflammatory rheumatisms with TNF blockers discriminate benign skin tumors from malignant skin lesions, requiring an appropriate referral to the dermatologist and a potential withdrawal or modification of the immunomodulatory treatment.</p><p>In the present study, we aimed to demonstrate whether an online course dedicated to the recognition of the most frequent benign and premalignant/malignant skin tumors increased the rheumatologists&#x02019; ability to identify these lesions.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><p>A nationwide randomized web-based survey was conducted online between October 1<sup>st</sup>, 2012 and October 1<sup>st</sup>, 2013. Starting from the French registry of rheumatologists (CEGEDIM registry), 420 rheumatologists all over France were solicited via e-mail. Written participant consent or institutional review board approval was not required because French law considers that it is not mandatory for non-interventional research and because this study did not involve patients but medical practitioners. No health or other identifying information was collected from the participants. All data collected (see <xref rid="pone.0127564.s002" ref-type="supplementary-material">S1 Text</xref>) were anonymized prior to author access and analysis. Physicians did not receive any financial or non-financial incitatives for participating in the survey.</p><p>Rheumatologists performed an initial online evaluation (Test 1, see <xref rid="pone.0127564.s001" ref-type="supplementary-material">S1 File</xref>), composed and scored as follows:</p><list list-type="bullet"><list-item><p>20 clinical cases (short text and pictures of skin lesions), for which participants had to indicate (i) if the skin lesion(s) were benign or premalignant/malignant (Score 1; range 0&#x02013;20; 0: no adequate diagnosis; 20: adequate diagnosis for all cases), (ii) their level of confidence in this diagnosis (benign or premalignant/malignant) measured on a 10-points Likert scale (Score 2; range 0&#x02013;10) and (iii) to identify the precise diagnosis of the skin lesion(s) among 5 diagnoses (Score 3; range 0&#x02013;20, 0: no correct diagnosis; 20: correct diagnosis for all cases)</p></list-item><list-item><p>5 multiple choice questionnaires of 5 response modalities each, testing the basic knowledge regarding skin cancers such as risk factors, adequate modalities of sun protection, prognosis of the different types of skin cancer, management of TNF blockers in case of history or diagnosis of skin cancer (Score 4; range 0&#x02013;25, 0: no correct answer; 25: 100% correct answers).</p></list-item></list><p>The clinical cases included the most frequent benign and premalignant/malignant skin tumors and were selected after unanimous validation by the board of dermatologists and rheumatologists. All pictures of skin lesions used were selected and presented in a way that did not allow the identification of the patient and the participants did not have any access to identify the patient. All patients provided a written consent before being photographed, allowing the use of the picture for educational purpose.</p><p>After Test 1, rheumatologists were randomized into 2 arms through the web site randomization module to ensure allocation concealment. Only participants randomized in the experimental arm received an online formation on skin tumors (Online training group), and attended consecutively 4 e-learning modules of 15 minutes each, consisting on a slide-show commented by a dermatologist of the board (<ext-link ext-link-type="uri" xlink:href="http://www.cri-net.com/formation/reussite.asp">http://www.cri-net.com/formation/reussite.asp</ext-link>), that they could split into several sessions (Module 1: Frequent benign skin tumors; Module 2: Risk factors and prevention of skin cancers; Module 3: Frequent skin cancers; Module 4: Prognosis of the different skin cancers). The formation was planned to be performed over a 3-weeks period after the baseline evaluation.</p><p>Participants were reevaluated (Test 2, similar to Test 1, but in a different order) 3 weeks after the end of the formation (online training group) and the initial evaluation (control group). The primary end-point was Score 1 (diagnosis of the benign <italic>vs</italic> premalignant/malignant nature of the lesions) at Test 2. The secondary end-points were Scores 2 to 4.</p><sec id="sec003"><title>Sample size calculation</title><p>A sample size of 70 rheumatologists per group was planned to detect a mean difference in the number of adequate diagnosis of 1 point (out of 20), assuming the common standard deviation of 1.8 with a 0.05 two-sided significance level with 90% power.</p></sec><sec id="sec004"><title>Analysis</title><p>The analysis was conducted on the intention-to-treat population (each randomized rheumatologist contributed to the initial group he was assigned). Comparisons of the mean scores obtained on Test 2 between trial arms were performed using a Student t test. Missing answers on Tests 2 were imputed by the corresponding answers on Test 1. Sensitivity analyses were performed to assess the impact of the treatment of missing values. Mean scores on Test 1 were compared by Student t test.</p><p>All statistical analyses were two-sided. The Type I error was fixed at 0.05. Statistical analyses were performed using R software v3.0.</p></sec></sec><sec sec-type="results" id="sec005"><title>Results</title><p>Altogether, 141 rheumatologists participated in the study (<xref rid="pone.0127564.g001" ref-type="fig">Fig 1</xref>), corresponding to a response rate of 34%. They were 74 females (52%), aged 44.9 years&#x000b1;11.1 (mean&#x000b1;SD), with 15.4&#x000b1;10.5 years of practice (mean&#x000b1;SD). The practice modalities was hospital practice in 74 (52%), private practice in 28 (20%) and 39 (28%) had a mixed hospital and private practice. Based on the declarations of participants, search for skin cancer risk factors, skin examination, or systematic yearly referral of patients with inflammatory rheumatisms to a dermatologist were rarely performed in patients receiving only conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) (<xref rid="pone.0127564.t001" ref-type="table">Table 1</xref>). Only 33% of rheumatologists give frequently photoprotection counseling, while, on the other hand, counseling patients regarding smoking cessation was performed by 85% of rheumatologists (not shown). In this subset of patients, the skin management was essentially left to the general practitioner, rather than to the dermatologist. In patients receiving biotherapy, search for skin cancer risk factors was performed by 63% of rheumatologists and half of them referred these patients to a dermatologist before starting biotherapy, and once a year thereafter. Only a third of rheumatologists performed by themselves skin examination before starting or during biotherapy (<xref rid="pone.0127564.t001" ref-type="table">Table 1</xref>).</p><fig id="pone.0127564.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.g001</object-id><label>Fig 1</label><caption><title>Study flow chart.</title></caption><graphic xlink:href="pone.0127564.g001"/></fig><table-wrap id="pone.0127564.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.t001</object-id><label>Table 1</label><caption><title>Rheumatologists&#x02019; habits regarding skin management in their patients.</title></caption><alternatives><graphic id="pone.0127564.t001g" xlink:href="pone.0127564.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Do you</th><th align="left" rowspan="1" colspan="1">Very often/Always</th><th align="left" rowspan="1" colspan="1">Never/Not often/Sometimes/Only if reported by the patient</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Search for skin cancer risk factors in all patients?</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1">84%</td></tr><tr><td align="left" rowspan="1" colspan="1">Search for skin cancer risk factors in patients with inflammatory rheumatism?</td><td align="left" rowspan="1" colspan="1">35%</td><td align="left" rowspan="1" colspan="1">65%</td></tr><tr><td align="left" rowspan="1" colspan="1">Search for skin cancer risk factors in patients with inflammatory rheumatism treated with BT?</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">37%</td></tr><tr><td align="left" rowspan="1" colspan="1">Perform complete skin examination before starting BT?</td><td align="left" rowspan="1" colspan="1">33%</td><td align="left" rowspan="1" colspan="1">67%</td></tr><tr><td align="left" rowspan="1" colspan="1">Refer to dermatologist before starting BT?</td><td align="left" rowspan="1" colspan="1">53%</td><td align="left" rowspan="1" colspan="1">47%</td></tr><tr><td align="left" rowspan="1" colspan="1">Perform skin examination during BT?</td><td align="left" rowspan="1" colspan="1">36%</td><td align="left" rowspan="1" colspan="1">64%</td></tr><tr><td align="left" rowspan="1" colspan="1">Refer to dermatologist once a year during BT?</td><td align="left" rowspan="1" colspan="1">48%</td><td align="left" rowspan="1" colspan="1">49%</td></tr><tr><td align="left" rowspan="1" colspan="1">Refer to GP for skin examination during BT?</td><td align="left" rowspan="1" colspan="1">30%</td><td align="left" rowspan="1" colspan="1">70%</td></tr><tr><td align="left" rowspan="1" colspan="1">Perform skin examination during DMARDs?</td><td align="left" rowspan="1" colspan="1">20%</td><td align="left" rowspan="1" colspan="1">80%</td></tr><tr><td align="left" rowspan="1" colspan="1">Refer to dermatologist once a year during DMARDs?</td><td align="left" rowspan="1" colspan="1">4.3%</td><td align="left" rowspan="1" colspan="1">95.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Refer to GP for skin examination during DMARDs?</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">35%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>BT: biotherapy treatment; GP: general practitioner; DMARDs: Disease Modifying Anti-Rheumatic Drugs</p></fn></table-wrap-foot></table-wrap><sec id="sec006"><title>Baseline recognition of skin tumors by rheumatologists</title><p>No significant differences on the different scores were found between groups at baseline, on Test 1 (<xref rid="pone.0127564.t002" ref-type="table">Table 2</xref>).</p><table-wrap id="pone.0127564.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.t002</object-id><label>Table 2</label><caption><title>Baseline evaluation of participating rheumatologists (Test 1).</title></caption><alternatives><graphic id="pone.0127564.t002g" xlink:href="pone.0127564.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Scores (range)</th><th align="left" rowspan="1" colspan="1">Online training group (n = 71)</th><th align="left" rowspan="1" colspan="1">Control group (n = 70)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mean score</th><th align="left" rowspan="1" colspan="1">Mean score</th><th align="left" rowspan="1" colspan="1">[CI 95%]</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1&#x000a0;: Benign <italic>vs</italic> premalignant/malignant (0&#x02013;20)</td><td align="char" char="." rowspan="1" colspan="1">11.3</td><td align="char" char="." rowspan="1" colspan="1">10.9</td><td align="left" rowspan="1" colspan="1">[-0.5&#x000a0;: 1.3]</td><td align="char" char="." rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x000a0;: Level of confidence (0&#x02013;10)</td><td align="char" char="." rowspan="1" colspan="1">5.2</td><td align="char" char="." rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">[-0.8&#x000a0;: 0.2]</td><td align="char" char="." rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">3&#x000a0;: Precise diagnosis (0&#x02013;20)</td><td align="char" char="." rowspan="1" colspan="1">9.3</td><td align="char" char="." rowspan="1" colspan="1">9.5</td><td align="left" rowspan="1" colspan="1">[-1.3&#x000a0;: 0.8]</td><td align="char" char="." rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x000a0;: MCQ (0&#x02013;25)</td><td align="char" char="." rowspan="1" colspan="1">19.9</td><td align="char" char="." rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">[-1.3&#x000a0;: 0.1]</td><td align="char" char="." rowspan="1" colspan="1">0.11</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>MCQ: multiple choice questionnaires</p></fn></table-wrap-foot></table-wrap><p>The lesions correctly identified as premalignant or malignant by more than half of the participants were Bowen&#x02019;s disease (<italic>i</italic>.<italic>e</italic> intraepithelial squamous cell carcinoma), both cutaneous and mucosal SCC and typical presentation of melanoma (<xref rid="pone.0127564.t003" ref-type="table">Table 3</xref>).</p><table-wrap id="pone.0127564.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.t003</object-id><label>Table 3</label><caption><title>Adequate identification of the premalignant/malignant nature of the skin lesions, before (Test 1) and after (Test 2) online training (or not).</title></caption><alternatives><graphic id="pone.0127564.t003g" xlink:href="pone.0127564.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Premalignant/malignant skin lesions</th><th colspan="2" align="center" rowspan="1">Online training group (n = 71)</th><th colspan="2" align="center" rowspan="1">Control group (n = 70)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Test 1</th><th align="left" rowspan="1" colspan="1">Test 2</th><th align="left" rowspan="1" colspan="1">Test 1</th><th align="left" rowspan="1" colspan="1">Test 2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AK 1<xref rid="t003fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">17 (24%)</td><td align="left" rowspan="1" colspan="1">33 (58%)</td><td align="left" rowspan="1" colspan="1">24 (34%)</td><td align="left" rowspan="1" colspan="1">23 (34%)</td></tr><tr><td align="left" rowspan="1" colspan="1">AK 2</td><td align="left" rowspan="1" colspan="1">23 (32%)</td><td align="left" rowspan="1" colspan="1">19 (33%)</td><td align="left" rowspan="1" colspan="1">16 (23%)</td><td align="left" rowspan="1" colspan="1">19 (28%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bowen&#x02019;s disease</td><td align="left" rowspan="1" colspan="1">41 (58%)</td><td align="left" rowspan="1" colspan="1">34 (60%)</td><td align="left" rowspan="1" colspan="1">38 (54%)</td><td align="left" rowspan="1" colspan="1">36 (54%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cutaneous SCC 1</td><td align="left" rowspan="1" colspan="1">40 (56%)</td><td align="left" rowspan="1" colspan="1">30 (53%)</td><td align="left" rowspan="1" colspan="1">38 (54%)</td><td align="left" rowspan="1" colspan="1">27 (40%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cutaneous SCC 2</td><td align="left" rowspan="1" colspan="1">65 (92%)</td><td align="left" rowspan="1" colspan="1">55 (96%)</td><td align="left" rowspan="1" colspan="1">63 (90%)</td><td align="left" rowspan="1" colspan="1">57 (85%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucosal SCC<xref rid="t003fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">46 (65%)</td><td align="left" rowspan="1" colspan="1">50 (88%)</td><td align="left" rowspan="1" colspan="1">50 (71%)</td><td align="left" rowspan="1" colspan="1">50 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">BCC 1<xref rid="t003fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">34 (48%)</td><td align="left" rowspan="1" colspan="1">38 (67%)</td><td align="left" rowspan="1" colspan="1">35 (50%)</td><td align="left" rowspan="1" colspan="1">32 (48%)</td></tr><tr><td align="left" rowspan="1" colspan="1">BCC 2<xref rid="t003fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">57 (80%)</td><td align="left" rowspan="1" colspan="1">52 (91%)</td><td align="left" rowspan="1" colspan="1">61 (87%)</td><td align="left" rowspan="1" colspan="1">56 (84%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">66 (93%)</td><td align="left" rowspan="1" colspan="1">55 (96%)</td><td align="left" rowspan="1" colspan="1">63 (90%)</td><td align="left" rowspan="1" colspan="1">59 (88%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acral achromic melanoma</td><td align="left" rowspan="1" colspan="1">33 (46%)</td><td align="left" rowspan="1" colspan="1">31 (54%)</td><td align="left" rowspan="1" colspan="1">26 (37%)</td><td align="left" rowspan="1" colspan="1">20 (30%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cutaneous lymphoma<xref rid="t003fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">2 (3%)</td><td align="left" rowspan="1" colspan="1">27 (47%)</td><td align="left" rowspan="1" colspan="1">2 (3%)</td><td align="left" rowspan="1" colspan="1">4 (6%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>AK: actinic keratosis; SCC: squamous cell carcinoma; BCC: basal cell carcinoma.</p></fn><fn id="t003fn002"><p>* lesions with difference before and after formation superior to 10 points in the online training group, while difference between Test 1 and Test 2 was inferior to 5 points in the control group</p></fn></table-wrap-foot></table-wrap><p>In contrast, the premalignant or malignant nature of actinic keratosis (AK), acral achromic melanoma and cutaneous lymphoma was not recognized by a vast majority of rheumatologists (<xref rid="pone.0127564.t003" ref-type="table">Table 3</xref>).</p><p>The lesions adequately identified as benign by more than 50% of participants were molluscum pendulum, dermatophytosis and dermatofibroma (<xref rid="pone.0127564.t004" ref-type="table">Table 4</xref>). Lesions wrongly identified as malignant were seborrheic keratosis (SK), comedone, ungueal hematoma, plantar wart, and epidermal cyst (<xref rid="pone.0127564.t004" ref-type="table">Table 4</xref>).</p><table-wrap id="pone.0127564.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.t004</object-id><label>Table 4</label><caption><title>Adequate identification of the benign nature of the skin lesions, before (Test 1) and after (Test 2) online training (or not).</title></caption><alternatives><graphic id="pone.0127564.t004g" xlink:href="pone.0127564.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Benign skin lesions</th><th colspan="2" align="center" rowspan="1">Online training group (n = 71)</th><th colspan="2" align="center" rowspan="1">Control group (n = 70)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Test 1</th><th align="left" rowspan="1" colspan="1">Test 2</th><th align="left" rowspan="1" colspan="1">Test 1</th><th align="left" rowspan="1" colspan="1">Test 2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SK 1<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">35 (49%)</td><td align="left" rowspan="1" colspan="1">36 (63%)</td><td align="left" rowspan="1" colspan="1">29 (41%)</td><td align="left" rowspan="1" colspan="1">30 (45%)</td></tr><tr><td align="left" rowspan="1" colspan="1">SK 2<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">31 (44%)</td><td align="left" rowspan="1" colspan="1">40 (70%)</td><td align="left" rowspan="1" colspan="1">24 (34%)</td><td align="left" rowspan="1" colspan="1">29 (43%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dermatofibroma<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">45 (63%)</td><td align="left" rowspan="1" colspan="1">48 (84%)</td><td align="left" rowspan="1" colspan="1">34 (49%)</td><td align="left" rowspan="1" colspan="1">44 (66%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Comedone<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">24 (34%)</td><td align="left" rowspan="1" colspan="1">34 (60%)</td><td align="left" rowspan="1" colspan="1">32 (46%)</td><td align="left" rowspan="1" colspan="1">26 (39%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ungueal Hematoma</td><td align="left" rowspan="1" colspan="1">29 (41%)</td><td align="left" rowspan="1" colspan="1">23 (40%)</td><td align="left" rowspan="1" colspan="1">18 (26%)</td><td align="left" rowspan="1" colspan="1">20 (30%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Plantar wart<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">35 (49%)</td><td align="left" rowspan="1" colspan="1">36 (63%)</td><td align="left" rowspan="1" colspan="1">21 (30%)</td><td align="left" rowspan="1" colspan="1">27 (40%)</td></tr><tr><td align="left" rowspan="1" colspan="1">MP</td><td align="left" rowspan="1" colspan="1">66 (93%)</td><td align="left" rowspan="1" colspan="1">56 (98%)</td><td align="left" rowspan="1" colspan="1">67 (96%)</td><td align="left" rowspan="1" colspan="1">65 (97%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Epidermal cyst<xref rid="t004fn002" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">32 (45%)</td><td align="left" rowspan="1" colspan="1">38 (67%)</td><td align="left" rowspan="1" colspan="1">21 (30%)</td><td align="left" rowspan="1" colspan="1">35 (52%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dermatophytosis</td><td align="left" rowspan="1" colspan="1">68 (96%)</td><td align="left" rowspan="1" colspan="1">47 (82%)</td><td align="left" rowspan="1" colspan="1">67 (96%)</td><td align="left" rowspan="1" colspan="1">64 (96%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>SK: Seborrheic keratosis; MP: Molluscum pendulum.</p></fn><fn id="t004fn002"><p>* lesions with difference before and after formation superior to 10 points in the online training group, while difference between Test 1 and Test 2 was inferior to 5 points in the control group</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec007"><title>Impact of the online formation</title><p>Regarding the primary evaluation criterion (Score 1: diagnosis of the benign vs premalignant/malignant nature of the lesions), the means difference in the number of adequate responses at Test 2 between groups was 2.2 points, favoring the online training group (IC95%: 1.3; 3.1), with a <italic>p</italic> value &#x0003c;0.0001 (<xref rid="pone.0127564.t005" ref-type="table">Table 5</xref>).</p><table-wrap id="pone.0127564.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0127564.t005</object-id><label>Table 5</label><caption><title>Impact of online training (Test 2).</title></caption><alternatives><graphic id="pone.0127564.t005g" xlink:href="pone.0127564.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Scores (range)</th><th align="left" rowspan="1" colspan="1">Online training group (n = 71)</th><th align="left" rowspan="1" colspan="1">Control group (n = 70)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mean score</th><th align="left" rowspan="1" colspan="1">Mean score</th><th align="left" rowspan="1" colspan="1">[CI 95%]</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1&#x000a0;: Benign <italic>vs</italic> premalignant/malignant (0&#x02013;20)</td><td align="char" char="." rowspan="1" colspan="1">13.4</td><td align="char" char="." rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1">[1.3: 3.1]</td><td align="left" rowspan="1" colspan="1">7.6x10<sup>-6</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x000a0;: Level of confidence (0&#x02013;10)</td><td align="char" char="." rowspan="1" colspan="1">5.6</td><td align="char" char="." rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">[-0.7&#x000a0;: 0.3]</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">3&#x000a0;: Precise diagnosis (0&#x02013;20)</td><td align="char" char="." rowspan="1" colspan="1">11.7</td><td align="char" char="." rowspan="1" colspan="1">9.6</td><td align="left" rowspan="1" colspan="1">[1.1&#x000a0;: 3.1]</td><td align="left" rowspan="1" colspan="1">9.3x10<sup>-5</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x000a0;: MCQ (0&#x02013;25)</td><td align="char" char="." rowspan="1" colspan="1">21.7</td><td align="char" char="." rowspan="1" colspan="1">20.8</td><td align="left" rowspan="1" colspan="1">[0.2: 1.7]</td><td align="left" rowspan="1" colspan="1">0.016</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>MCQ: multiple choice questionnaires</p></fn></table-wrap-foot></table-wrap><p>A significant difference at Test 2 was also found for Scores 3 and 4. Finally, the level of confidence of the rheumatologists (Score 2) was not statistically different between groups (<xref rid="pone.0127564.t005" ref-type="table">Table 5</xref>).</p><p>We identified several lesions where the formation allowed an important better recognition of the benign or malignant nature of the tumor (difference before and after formation superior to 10 points in the trained group, while difference between Test 1 and Test 2 was inferior to 5 points in the control group): BCC, mucosal SCC, cutaneous lymphoma, AK for malignant/premalignant lesions (<xref rid="pone.0127564.t003" ref-type="table">Table 3</xref>); SK, plantar wart, dermatofibroma, comedone, epidermal cyst for benign lesions (<xref rid="pone.0127564.t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>Our study suggests that French rheumatologists appear poorly concerned about the risk of skin cancers in patients with inflammatory rheumatism treated with cDMARDs and follow poorly the national recommendations since search for skin cancer risk, skin examination or dermatologist referral is performed by a minority of participating rheumatologists. In theory, the French Society of Rheumatology indeed recommends that any patient affected with chronic inflammatory rheumatism should be examined at least once by a dermatologist, with an annual check-up in case of past history of skin cancer, fair skin or hair, regular and repeated sun exposure, past photo-therapy, multiple nevi, immunosuppressive treatment (prednisone &#x0003e;20 mg/d) and past treatment with radiotherapy. In the same line, the COMORA study evaluating RA monitoring also found that an optimal screening for skin cancers, at least one examination of RA patients by a dermatologist and yearly referral if more than 40 nevi are present, was performed in only 23.9% of the patients [<xref rid="pone.0127564.ref009" ref-type="bibr">9</xref>]. Much more concern is given to patients receiving biotherapy but only half of the participant rheumatologists referred yearly to the dermatologist, despite the national annual check-up recommendation of the French Club Rhumatismes et Inflammation (CRI) [<xref rid="pone.0127564.ref010" ref-type="bibr">10</xref>].</p><p>On the contrary, a greater concern regarding smoking cessation in patients affected with chronic inflammatory rheumatism was observed in participating rheumatologists, probably not only due to the increased risk of developing lung cancer in these patients but also to the well-established impact of smoking on disease activity and response to treatment.</p><p>Because of a limited access to a dermatologist in several countries [<xref rid="pone.0127564.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0127564.ref012" ref-type="bibr">12</xref>], it appeared original and of interest to provide a dedicated formation to rheumatologists dealing with a population at increased risk of skin cancers. The baseline evaluation of rheumatologists identified a satisfactory global cognitive knowledge about skin cancers and a global good level of recognition of several benign or malignant skin lesions when presenting themselves in their typical type. In contrast, most &#x0201c;black tumors&#x0201d; were wrongly considered as malignant (SK, comedone, haematoma), the premalignant nature of AK was not recognized and cutaneous lymphoma, which represents a classical differential diagnosis for psoriasis, were completely unknown by a vast majority of participating rheumatologists.</p><p>However, rheumatologists who received the online formation obtained a better cognitive knowledge on skin tumors, were more able to identify the malignant or non-malignant nature of skin lesions and also to precisely identify the different skin lesions. Trained rheumatologists also significantly improved their baseline scores after the formation. More specifically, recognition of AK as premalignant lesions and of cutaneous lymphoma as malignant lesions was considerably improved, as well as the recognition of SK as benign lesions.</p><p>Altogether, the major strengths of our study are 1) that we have performed a rigorous assessment of this online training, using a randomized trial, which is rarely performed in the educational field; 2) this trial has included a large number and a wide pattern of participants (hospital practice, private practice or mixed practice) which guaranties an excellent external validity; 3) the primary end point is very relevant to clinical practice (malignant lesion requiring urgent referral to the dermatologist/ benign lesion not requiring referral to the dermatologist); 4) the formation to skin tumors was not dedicated to general practitioners but to rheumatologists and this training also aimed at improving knowledge regarding benign skin tumors. The limits of our study include a 34% response rate that could have selected rheumatologists basically more interested in the field of skin tumors (however, this response rate is usual in web-based surveys), and the absence of long term evaluation in order to test the maintenance of the positive impact of the formation. It would be now interesting to evaluate the impact of the formation on the rheumatologist practice regarding skin cancers in patients with inflammatory rheumatisms and to identify if the formation has modified the referral of patients to the dermatologist, allowing the diagnosis of more malignant tumors and limiting the referral for benign tumors.</p></sec><sec sec-type="supplementary-material" id="sec009"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0127564.s001"><label>S1 File</label><caption><title>Baseline test performed by the rheumatologists (Test 1).</title><p>(PDF)</p></caption><media xlink:href="pone.0127564.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0127564.s002"><label>S1 Text</label><caption><title>Questionnaire assessing the rheumatologists habits regarding skin cancer detection.</title><p>(PDF)</p></caption><media xlink:href="pone.0127564.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are thankful to all the rheumatologists who participated in the study, to Charles Dufrene and Yannick Darras (AEI) for technical assistance, to Dr Eric Sauvage and Mrs Sophie Carret (Abbvie Ltd) and to the board of directors of the Club Rhumatismes et Inflammation (Zahir Amoura, Olivier Benveniste, Olivier Boyer, Patrick Durez, Bruno Fautrel, Pierre-Andr&#x000e9; Guerne, Eric Hachulla, Denis Jullien, Luc Mouthon, Thao Pham, Xavier Puechal, J&#x000e9;r&#x000e9;mie Sellam, Jean Sibilia) for their help in conducting this study.</p></ack><ref-list><title>References</title><ref id="pone.0127564.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Mercer</surname><given-names>L</given-names></name>, <name><surname>Green</surname><given-names>AC</given-names></name>, <name><surname>Galloway</surname><given-names>JB</given-names></name>, <name><surname>Davies</surname><given-names>R</given-names></name>, <name><surname>Lunt</surname><given-names>M</given-names></name>, <name><surname>Dixon</surname><given-names>WG</given-names></name>, <etal>et al</etal>
<article-title>The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register</article-title>. <source>Ann Rheum Dis</source>. <year>2012</year>; <volume>71</volume>: <fpage>869</fpage>&#x02013;<lpage>874</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2011-200622">10.1136/annrheumdis-2011-200622</ext-link></comment>
<pub-id pub-id-type="pmid">22241900</pub-id></mixed-citation></ref><ref id="pone.0127564.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Askling</surname><given-names>J</given-names></name>, <name><surname>Fored</surname><given-names>CM</given-names></name>, <name><surname>Brandt</surname><given-names>L</given-names></name>, <name><surname>Baecklund</surname><given-names>E</given-names></name>, <name><surname>Bertilsson</surname><given-names>L</given-names></name>, <name><surname>Feltelius</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists</article-title>. <source>Ann Rheum Dis</source>. <year>2005</year>; <volume>64</volume>: <fpage>1421</fpage>&#x02013;<lpage>1426</lpage>.
<pub-id pub-id-type="pmid">15829572</pub-id></mixed-citation></ref><ref id="pone.0127564.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Mellemkjaer</surname><given-names>L</given-names></name>, <name><surname>Linet</surname><given-names>MS</given-names></name>, <name><surname>Gridley</surname><given-names>G</given-names></name>, <name><surname>Frisch</surname><given-names>M</given-names></name>, <name><surname>M&#x000f8;ller</surname><given-names>H</given-names></name>, <name><surname>Olsen</surname><given-names>JH</given-names></name>. <article-title>Rheumatoid arthritis and cancer risk</article-title>. <source>Eur J Cancer</source>
<year>1996</year>; <volume>32A</volume>: <fpage>1753</fpage>&#x02013;<lpage>1757</lpage>.
<pub-id pub-id-type="pmid">8983286</pub-id></mixed-citation></ref><ref id="pone.0127564.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Mariette</surname><given-names>X</given-names></name>, <name><surname>Matucci-Cerinic</surname><given-names>M</given-names></name>, <name><surname>Pavelka</surname><given-names>K</given-names></name>, <name><surname>Taylor</surname><given-names>P</given-names></name>, <name><surname>van Vollenhoven</surname><given-names>R</given-names></name>, <name><surname>Heatley</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year>; <volume>70</volume>: <fpage>1895</fpage>&#x02013;<lpage>1904</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2010.149419">10.1136/ard.2010.149419</ext-link></comment>
<pub-id pub-id-type="pmid">21885875</pub-id></mixed-citation></ref><ref id="pone.0127564.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Mariette</surname><given-names>X</given-names></name>, <name><surname>Vaughan</surname><given-names>Reynolds A</given-names></name>, <name><surname>Emery</surname><given-names>P</given-names></name>. <article-title>Updated meta-analysis of non melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors</article-title>. <source>Ann Rheum Dis</source>. <year>2012</year>; <volume>71</volume>: <fpage>e2</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2012-202478">10.1136/annrheumdis-2012-202478</ext-link></comment>
<pub-id pub-id-type="pmid">23014259</pub-id></mixed-citation></ref><ref id="pone.0127564.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Wolfe</surname><given-names>F</given-names></name>, <name><surname>Michaud</surname><given-names>K</given-names></name>. <article-title>Biologic treatment of rheumatoid arthritis and the risk of malignancy</article-title>. <source>Arthritis Rheum</source>. <year>2007</year>; <volume>56</volume>: <fpage>2886</fpage>&#x02013;<lpage>2895</lpage>.
<pub-id pub-id-type="pmid">17729297</pub-id></mixed-citation></ref><ref id="pone.0127564.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Askling</surname><given-names>J</given-names></name>, <name><surname>Fahrbach</surname><given-names>K</given-names></name>, <name><surname>Nordstrom</surname><given-names>B</given-names></name>, <name><surname>Ross</surname><given-names>S</given-names></name>, <name><surname>Schmid</surname><given-names>CH</given-names></name>, <name><surname>Symmons</surname><given-names>D</given-names></name>. <article-title>Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials with adalimumab, etanercept, and infliximab using patient level data</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2011</year>; <volume>20</volume>: <fpage>119</fpage>&#x02013;<lpage>130</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pds.2046">10.1002/pds.2046</ext-link></comment>
<pub-id pub-id-type="pmid">21254282</pub-id></mixed-citation></ref><ref id="pone.0127564.ref008"><label>8</label><mixed-citation publication-type="journal">
<collab>Askling J on behalf of the ARTIS Study Group</collab>. <article-title>Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS Registry 1998&#x02013;2006</article-title>. <source>Ann Rheum Dis</source>. <year>2009</year>; <volume>68</volume>
<issue>Suppl 3</issue>: <fpage>423</fpage>.</mixed-citation></ref><ref id="pone.0127564.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Dougados</surname><given-names>M</given-names></name>, <name><surname>Soubrier</surname><given-names>M</given-names></name>, <name><surname>Antunez</surname><given-names>A</given-names></name>, <name><surname>Balint</surname><given-names>P</given-names></name>, <name><surname>Balsa</surname><given-names>A</given-names></name>, <name><surname>Buch</surname><given-names>MH</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year>; <volume>73</volume>: <fpage>62</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2013-204223">10.1136/annrheumdis-2013-204223</ext-link></comment>
<pub-id pub-id-type="pmid">24095940</pub-id></mixed-citation></ref><ref id="pone.0127564.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Pham</surname><given-names>T</given-names></name>, <name><surname>Bachelez</surname><given-names>H</given-names></name>, <name><surname>Berthelot</surname><given-names>JM</given-names></name>, <name><surname>Blacher</surname><given-names>J</given-names></name>, <name><surname>Bouhnik</surname><given-names>Y</given-names></name>, <name><surname>Claudepierre</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>TNF alpha antagonist therapy and safety monitoring</article-title>. <source>Joint Bone Spine</source>
<year>2011</year>; <volume>78</volume>
<issue>Suppl 1</issue>: <fpage>15</fpage>&#x02013;<lpage>185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1297-319X(11)70001-X">10.1016/S1297-319X(11)70001-X</ext-link></comment>
<pub-id pub-id-type="pmid">21703545</pub-id></mixed-citation></ref><ref id="pone.0127564.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Grange</surname><given-names>F</given-names></name>, <name><surname>Woronoff</surname><given-names>AS</given-names></name>, <name><surname>Bera</surname><given-names>R</given-names></name>, <name><surname>Colomb</surname><given-names>M</given-names></name>, <name><surname>Lavole</surname><given-names>B</given-names></name>, <name><surname>Fournier</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of a general practitioner training campaign for early detection of melanoma in France</article-title>. <source>Br J Dermatol</source>. <year>2014</year>; <volume>170</volume>: <fpage>123</fpage>&#x02013;<lpage>129</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bjd.12585">10.1111/bjd.12585</ext-link></comment>
<pub-id pub-id-type="pmid">23937244</pub-id></mixed-citation></ref><ref id="pone.0127564.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Geller</surname><given-names>AC</given-names></name>, <name><surname>Swetter</surname><given-names>SM</given-names></name>, <name><surname>Oliveria</surname><given-names>S</given-names></name>, <name><surname>Dusza</surname><given-names>S</given-names></name>, <name><surname>Halpern</surname><given-names>AC</given-names></name>. <article-title>Reducing mortality in individuals at high risk for advanced melanoma through education and screening</article-title>. <source>J Am Acad Dermatol</source>. <year>2011</year>; <volume>65</volume>
<issue>Suppl 1</issue>: <fpage>587</fpage>&#x02013;<lpage>594</lpage>.</mixed-citation></ref></ref-list></back></article>